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Abstract
Background: There is growing evidence that specialized clinical services targeted toward individuals early in the
course of a psychotic illness may be effective in reducing both the clinical and economic burden associated with
these illnesses. Unfortunately, the United States has lagged behind other countries in the delivery of specialized,
multi-component care to individuals early in the course of a psychotic illness. A key factor contributing to this lag
is the limited available data demonstrating the clinical benefits and cost-effectiveness of early intervention for
psychosis among individuals served by the American mental health system. Thus, the goal of this study is to present
clinical and cost outcome data with regard to a first-episode psychosis treatment center within the American mental
health system: the Early Psychosis Intervention Center (EPICENTER).
Methods: Sixty-eight consecutively enrolled individuals with first-episode psychosis completed assessments of
symptomatology, social functioning, educational/vocational functioning, cognitive functioning, substance use,
and service utilization upon enrollment in EPICENTER and after 6 months of EPICENTER care. All participants were
provided with access to a multi-component treatment package comprised of cognitive behavioral therapy, family
psychoeducation, and metacognitive remediation.
Results: Over the first 6 months of EPICENTER care, participants experienced improvements in symptomatology,
social functioning, educational/vocational functioning, cognitive functioning, and substance abuse. The average
cost of care during the first 6 months of EPICENTER participation was lower than the average cost during the 6-months
prior to joining EPICENTER. These savings occurred despite the additional costs associated with the receipt of
EPICENTER care and were driven primarily by reductions in the utilization of inpatient psychiatric services and
contacts with the legal system.
Conclusions: The results of our study suggest that multi-component interventions for first-episode psychosis provided
in the US mental health system may be both clinically-beneficial and cost-effective. Although additional research is
needed, these findings provide preliminary support for the growing delivery of specialized multi-component
interventions for first-episode psychosis within the United States.
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Background
Psychotic disorders exert a significant burden under
current systems of care worldwide. Despite advances in
the treatment of these disorders, individuals with psych-
osis typically experience a course of illness characterized
by repeated relapses of psychotic symptoms [1], persist-
ent unemployment [2], limited social relationships [3],
and premature mortality [4]. Not surprisingly, the cost
of care for psychotic disorders is astronomical. For ex-
ample, within the United States, the cost of care in 2002
for a single psychotic disorder (i.e., schizophrenia) was
nearly 63 billion dollars [5], suggesting that in 2015 the
cost will exceed $81 billion dollars after adjusting for
inflation [6].
There is growing evidence that specialized clinical ser-
vices targeted toward individuals early in the course of a
psychotic illness may be effective in reducing both the
clinical and economic burden associated with these ill-
nesses [7–11]. The success of these early intervention ser-
vices has sparked significant health services reform
worldwide, including the establishment of a national early
intervention service network in the United Kingdom [12]
and the funding of a similar national care system by the
federal government of Australia [13].
Unfortunately, the United States has lagged behind
other countries in the delivery of specialized, multi-
component care to individuals early in the course of a
psychotic illness [14]. A key factor contributing to this
lag is the limited available data demonstrating the clin-
ical benefits and cost-effectiveness of early interven-
tion for psychosis among individuals served by the
American mental health system ([14, 15], however, see
[11, 16, 17]). Consequently, there is a clear need for
additional systematic evaluations of multi-component
treatment packages for individuals with first-episode
psychosis in the United States.
Thus, the goal of this manuscript is twofold. First, we
will review the process of developing a multi-component
treatment program for individuals with first-episode psych-
osis within the American mental health system: the Early
Psychosis Intervention Center (EPICENTER: [18, 19]).
Established in 2010 within the Department of Psychiatry at
the University of Arizona, this program serves a catchment
area of approximately 1 million individuals in the south-
west United States. Second, we will review clinical and cost
data among EPICENTER participants during the 6 months
prior to joining EPICENTER as compared to during the
first 6 months of EPICENTER care. The purpose of this
activity is to quantify the possible clinical and economic
benefits associated with EPICENTER participation.
Methods
Human subject research completed as part of this pro-
ject was approved by the University of Arizona Institu-
tional Review Board (Project Numbers 09-1113-02 and
10-0440-02) and was completed in compliance with the
Helsinki Declaration.
Participants
Participants in this study were the first 68 individuals
with first-episode psychosis consecutively enrolled at
EPICENTER. Eligibility criteria for EPICENTER in-
clude: diagnosis of a schizophrenia-spectrum disorder
or affective disorder with psychotic features as deter-
mined using the Structured Clinical Interview for the
DSM-IV-TR [20]; onset of psychotic symptoms within
the past 5 years per the Symptom Onset in Schizophre-
nia Inventory [21]; ages 15–35; and no evidence of
mental retardation or organic brain impairment as evi-
denced by a premorbid IQ greater than 70 as estimated
using the Reading subtest of the Wide Range Achieve-
ment Test [22]. Among the current sample, there were
49 men and 19 women with an average age of 22.71 years.
The median duration of time since the onset of psychotic
symptoms was 16.76 months. The distribution of psych-
otic disorder diagnoses is summarized in Fig. 1. Seventy-
eight percent were prescribed antipsychotic medication
prior to enrollment in EPICENTER, and none had previ-
ously participated in evidence-based psychosocial treat-
ment for psychosis.
During the time in which these 68 individuals were
consecutively enrolled in EPICENTER, a total of 264
individuals were referred to this clinical service. Forty-
seven of these referred individuals were excluded from
participation due to being younger than 15 years (n =
17), not having psychosis (n = 12), having a first onset
of psychotic symptoms > 5 years prior (n = 10), being
older than 35 years (n = 4), having an estimated pre-
morbid IQ < 70 (n = 2), having psychosis resulting from
a general medical condition (n = 1), and having attenu-
ated psychotic symptoms that did not meet DSM-IV
criteria for a psychotic disorder (n = 1). An additional
149 were referred to the study but declined to partici-
pate in the eligibility assessment.
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Written informed consent with regard to study partici-
pation was obtained from all adult subjects. For partici-
pants under the age of 18, written informed consent was
obtained from the participant’s parent or guardian and
written assent was obtained from the participant.
Procedures
Individuals with first-episode psychosis completed the mea-
sures described below as part of a larger research battery de-
signed to investigate mediators and moderators of treatment
response among individuals with first-episode psychosis
[19, 23]. All measures were administered upon enrollment
in EPICENTER and after 6 months of participation in
EPICENTER services. When possible, assessments were
administered by blinded researchers. However, in some in-
stances, baseline assessments (i.e., assessments completed
prior to the start of EPICENTER care) were completed by
EPICENTER clinical staff due to staffing limitations.
Measures
Symptomatology
Severity of psychotic symptoms was assessed using the
Positive and Negative Syndrome Scale (PANSS: [24]). The
PANSS is a 30-item clinician-rated scale that assesses three
domains of symptomatology: positive symptoms, negative
symptoms, and general symptoms. Items are rated such
that higher scores are indicative of worse symptomatology.
Social and educational/vocational functioning
The Social Functioning Scale (SFS: [25]) was used to meas-
ure social functioning among study participants. This 79-
item questionnaire assesses six domains of social function-
ing: social engagement/withdrawal; interpersonal behavior/
communication; participation in prosocial activities; partici-
pation in recreational activities; independence-competence;
and independence-performance. Each domain is scored
such that higher scores are indicative of better functioning.
A total social functioning score was calculated by summing
all SFS subscales into a single variable.
The SFS also provides data with regard to participants’
level of educational/vocational functioning on a 0–10
scale ranging from no perceived capability to work and
no active efforts to find a job (0) to participation in full
time work/school (10). Consistent with past analyses of
educational/vocational functioning among individuals
with first-episode psychosis using the SFS [17], these
scores were transformed into a dichotomous categorical
variable defined as employed/in school (i.e., part-time or
greater participation in competitive work/school) versus
unemployed/not in school.
Cognitive functioning
The MATRICS Consensus Cognitive Battery (MCCB:
[26]) was utilized to assess cognitive functioning among
study participants. This battery assesses seven domains
of cognitive functioning: (i) processing speed; (ii) atten-
tion/vigilance; (iii) working memory; (iv) verbal learning;
(v) visual learning; (vi) reasoning and problem-solving;
and (vii) social cognition. An overall index of cognitive
functioning is also computed. Scores are reported as T-
scores with higher scores indicative of greater cognitive
functioning. The MATRICS offers alternate versions of






















Fig. 1 Distribution of Psychotic Disorder Diagnoses among EPICENTER Participants
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tests used to assess verbal learning and reasoning and
problem-solving to reduce the effect of practice on results
from trials in which these measures are administered mul-
tiple times. We utilized these alternate forms in the current
study and the order in which original and alternate forms
were administered was counterbalanced across participants.
Substance use
The severity of participants’ substance use was assessed
using the Alcohol Use Scale/Drug Use Scale (AUS/DUS:
[27]). The AUS/DUS is a clinician-rated scale that assesses
use of 12 substances: tobacco, alcohol, marijuana/THC,
cocaine, opiates, phencyclidine (PCP), amphetamines, 3,4-
methylenedioxy-N-methylamphetamine (MDMA), gama-
hydroxy butarate (GHB) or flunitrazepam (Rohypnol),
huffing of glue or other volatiles, hallucinogens, and other
substances of abuse not otherwise specified. Severity of
participants’ use is rated on a 5-point scale based on
DSM-IV-TR criteria for severity of use: (1) abstinent; (2)
use without impairment; (3) abuse; (4) dependence; and
(5) dependence with institutionalization. Based on these
ratings, participants’ were assigned an overall substance
use score using the same 5-point scale. This overall score
was calculated as the highest severity ranking earned by a
participant across all 12 substance categories.
Service utilization and cost-effectiveness
The Service Utilization and Resources Form for Schizo-
phrenia (SURF: [28]) was used to assess participants’
utilization of psychiatric and legal resources. With re-
gard to psychiatric resources, we tracked participants’
use of EPICENTER services as well as non-EPICENTER
outpatient mental health services that participants may
have chosen to utilize during study participation (e.g.,
case management, medication management, etc.). Cost
outcomes for EPICENTER participants were calcu-
lated using cost estimates associated with inpatient
hospitalization in Arizona [29] and contact with the
legal system [30]. Data with regard to financial sup-
port provided by family members was assessed directly
in the SURF. Costs associated with unemployment and
non-participation in competitive education among young
adults were obtained from a recent report from the Cor-
poration for National and Community Service and the
White House Council for Community Solutions [31] and
included costs associated with lost wages, poor health,
and contact with the legal system as well as savings associ-
ated with reduced use of government subsidies designed
to support participation in higher education. Given that
we already obtained estimates of costs associated with
contact with the legal system elsewhere, these costs were
not included when calculating the total costs associated
with unemployment and non-participation in competitive
education.
Antipsychotic medication use was assessed using the
current medication form—a measure used in past stud-
ies of first-episode psychosis [32, 33]. Antipsychotic
medications were converted to chlorpromazine equiva-
lents using the conversion values developed by Leucht
and colleagues [34] and Woods [35]. Costs for anti-
psychotic medication used by EPICENTER participants
were calculated using 2015 prices for non-generic anti-
psychotic medication.
Costs for EPICENTER services were calculated using
salary and benefits cost data for EPICENTER clinical
staff and indirect cost estimates from the hospital
where the program is located. Similar to a previous
cost-effectiveness evaluation of clinical services for
first-episode psychosis [9], costs for non-EPICENTER
outpatient mental health services were calculated by
multiplying the number of such services by the hourly
rate for a mental health counselor as reported in the
2013 National Occupational Employment and Wage
Estimates for the United States [36]. Indirect costs for
non-EPICENTER outpatient mental health services
were calculated using the same indirect rates used for
EPICENTER outpatient mental health services. All cost
estimates were adjusted to 2015 values to correct for
inflation.
Multi-component intervention
The components of the EPICENTER intervention pack-
age were selected following a series of meetings with
mental health stakeholders in our local community.
Stakeholders included administrators and practitioners
in the public and private mental health systems, mem-
bers of local advocacy groups, and individuals with a
mental illness. In these meetings, stakeholders identified
access to evidence-based psychosocial interventions as
the key treatment need of individuals with first-episode
psychosis in our community. Stakeholders verified that
the need for psychiatric medication was successfully ad-
dressed by existing resources in our community. This
information is consistent with existing data on access to
evidence-based psychosocial interventions [37–39] and
antipsychotic medication [37, 39] published by other
research groups in the United States.
Thus, to avoid duplication of existing services, we
limited the components of the EPICENTER multi-
component treatment package solely to evidence-based
psychosocial interventions for psychosis that were
otherwise unavailable in our community. All partici-
pants interested in receiving antipsychotic medication
were able to do so through community providers not
affiliated with the study. Selection of components of
this treatment package was determined based on the a
priori goals to (i) balance the need to address the psy-
chiatric symptomatology and functional deficits (e.g.,
Breitborde et al. BMC Psychiatry  (2015) 15:266 Page 4 of 11
cognitive functioning deficits) that are part of the core
pathology of psychotic disorders with the goal of pro-
viding the least time-intensive intervention package for
individuals with psychosis [40, 41]; (ii) incorporate in-
terventions that could be applied with fidelity while
simultaneously being flexible enough to be responsive to
the varying needs of EPICENTER participants [42, 43];
(iii) address the unique gaps in treatment experienced
by individuals with psychosis in our catchment area
(i.e., limited access to evidence-based psychosocial in-
terventions); and (iv) be delivered effectively given the
available staffing resources which ranged from approxi-
mately 0.5 to 1.0 full-time positions during the course
of the study. The resulting intervention package was
comprised of three components: cognitive behavioral
therapy, family psychoeducation, and cognitive remedi-
ation. Evidence from the study of each respective com-
ponent suggests that this combined treatment package
may address both the symptomatology [44–47] and
functional deficits [48–50] common among individuals
with psychotic disorders. To increase the flexibility of
this intervention package, we selected interventions
that could be delivered individually or in group format.
Staffing limitations precluded the inclusion of certain
evidence-based treatments (e.g., supported employment
and education) for which a dedicated full-time staff
member is recommended [51, 52].
Upon enrollment in EPICENTER, participants were pro-
vided with education with regard to the different elements
of the multi-component intervention package. Participants
were then allowed to choose which interventions they
would complete during their care at EPICENTER.
Cognitive Behavioral Therapy (CBT)
CBT is an evidence-based treatment for individuals
with psychotic disorders [53] with demonstrated effi-
cacy in both individual [54] and group formats [55]. Of
note, though, a recent meta-analysis published after the
launch of EPICENTER has called into question the effi-
cacy of this intervention for individuals with psychosis
[56]. At EPICENTER we have opted to provide CBT in
both an individual and group format. In both formats,
we utilize well-established strategies for addressing the
positive and negative symptoms that accompany psych-
otic disorders [57–59] as well as the other sequelae that
accompany psychotic disorders, including anxiety [46],
insomnia [60], post-traumatic stress disorder [61, 62],
substance use [63], and deficits in social and vocational
functioning [64–66]. The focus of the intervention is
tailored to the specific needs and motivation of the in-
dividual with first-episode psychosis such that EPICEN-
TER participants, in collaboration with their therapist,
identify the specific therapeutic targets to address in
CBT sessions.
Family Psychoeducation (FP)
Family psychoeducation is an evidence-based treatment
for psychotic disorders [45]. The FP intervention utilized
at EPICENTER [67] was based on the protocol developed
by McFarlane and colleagues [45] and was modified to ad-
dress the uniques strengths and challenges of individuals
with first-episode psychosis. This intervention involves
two modules: (i) joining, (ii) family problem-solving ses-
sions. During the joining module, caregiving relatives meet
individually with a clinician for one to three sessions to
discuss the patient’s clinical history, the family’s experi-
ence and understanding of their relative’s illness, and
family members’ concerns and questions with regard to
participating in a multifamily group. Following the
completion of the joining module, families and their ill
relatives have the option to participate in regular family
problem-solving sessions (2× per month). During the
problem-solving sessions, caregivers and ill relatives iden-
tify challenges or problems occurring in their life and
evaluate possible solutions to these problems through a
structured problem-solving activity. Of note, the family
problem-solving sessions, which are the primary compo-
nent of this FP intervention, are delivered in either a mul-
tifamily group or single family format [68] depending on
the preference of the family.
Metacognitive Remediation (MCR)
Cognitive remediation, which is recognized as a “best
practice” in the treatment of psychotic disorders [69, 70],
is typically comprised of a series of repeated exercises de-
livered by a clinician or via a computer that are designed
to improve cognitive functioning.
At EPICENTER, participants received metacognitive
remediation (MCR: [71, 72])—a form of cognitive re-
mediation shown to improve numerous domains of cog-
nitive functioning among individuals with first-episode
psychosis, including processing speed, attention/vigi-
lance, working memory, verbal learning, visual learning,
reasoning and problem-solving, and social cognition
[71]. MCR involves participation in both computerized
cognitive remediation exercises and metacognitive skills
development exercises with a clinician. With regard to
the former, participants were provided with the comput-
erized CR program PSSCogRehab [73]—a program fre-
quently used in past studies of cognitive remediation in
psychotic disorders [74–80]. This program provides par-
ticipants with training in four areas of cognitive function-
ing: cognitive foundations (e.g., attention and processing
speed), visual-spatial abilities, memory, and problem-
solving abilities. Participants initially complete simple
tasks in each domain and, once mastered, gradually pro-
gress to more difficult tasks. Following each attempt to
complete a PSSCogRehab exercise, individuals with first-
episode psychosis participate in a “metacognitive
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discussion” with a clinician designed to promote metacog-
nitive skills development and facilitate transfer of
knowledge/skills developed during the MCR session to
real-world situations. Of note, not all EPICENTER par-
ticipants were able to complete MCR during the first 6
months of EPICENTER care due to their participation
in another study in which they were randomized not to
receive this intervention during the first 6 months of
care [81]. In addition, the first 10 EPICENTER partici-
pants to receive cognitive remediation did so before the
development of MCR, and so completed the same
PSSCogRehab tasks but did not participate in metacog-
nitive discussions as described above.
Statistical analyses
All data were analyzed following the intention to treat
principle [82]. Consistent with current statistical guide-
lines [83, 84], missing data were addressed using mul-
tiple imputation [85, 86]. To facilitate the completion of
these analyses, change scores were calculated for con-
tinuous variables by subtracting baseline assessment
values from 6-month assessment values. These values
were then analyzed using t-tests. For the investigation of
within-subject change in categorical variables, t-values
were calculated using effect sizes and standard errors
combined using Rubin’s rule [86, 87]. As degrees of free-
dom calculated using standard metrics for t-tests are
overly liberal in the analysis of multiply imputed data,
we adjusted the degrees of freedom for our analyses
using the formula develop by Barnard and Rubin [88].
Participants who completed both the baseline and 6-
month assessments did not differ from those who only
completed baseline assessments with regard to symp-
tomatology, cognitive functioning, and most domains of
substance use and social functioning. Individuals who
did not complete the 6-month assessment reported
higher use of marijuana and lower use of tobacco at
baseline compared to individuals who completed both
the baseline and 6-month assessment. Additionally, indi-
viduals who did not complete the 6-month assessment
reported better interpersonal communication and com-
petence with regard to the completion of independent
tasks of daily living as assessed by the SFS as compared




Rates of participation in EPICENTER interventions are
summarized in Table 1. Among all interventions, individ-
ual CBT was the most utilized intervention with 61 % of
individuals with first-episode psychosis participating in
this intervention. Individuals with first-episode psychosis
were more likely to participate in individual CBT as
compared to group CBT (39 %: t = 3.72; p < 0.01). Con-
versely, families were more likely to participate in multifam-
ily (i.e., group) psychoeducation (44 %) as compared to
individual family psychoeducation (22 %: t = 4.38; p < 0.01).
Symptomatology
Baseline and 6-month follow-up scores for PANSS are
presented in Table 2. Over the first 6 month of care, par-
ticipants experienced reduction in both positive (t = −3.93;
p < 0.01) and general symptoms (t = −4.48; p < 0.01). There
Table 1 Rates of participation in EPICENTER interventions
Intervention Rate of Participation n(%)
Cognitive Behavioral Therapy—Individual 47(61 %)
Cognitive Behavioral Therapy—Group 30(39 %)
Family Psychoeducation—Individual 17(22 %)
Family Psychoeducation—Group 34(44 %)
Metacognitive Remediation 19(25 %)
Table 2 Symptomatology, social functioning, cognition, and
substance use at baseline and after 6 months of epicenter care
Baseline Six Months
PANSS
1) Positive Symptoms 15.53 13.03*
2) Negative Symptoms 15.07 13.52
3) General Symptoms 30.41 26.29*
SFS
1) Social Engagement 9.77 9.78
2) Interpersonal Communication 6.60 7.22
3) Prosocial Activities 15.44 18.77
4) Recreation 18.32 20.37
5) Independence-Competence 33.93 36.07*
6) Independence–Performance 22.85 25.47
MCCB
1) Processing Speed 35.39 41.29*
2) Attention/Vigilance 36.83 38.85
3) Working Memory 40.11 46.59
4) Verbal Learning 40.02 43.98*
5) Visual Learning 38.07 44.89
6) Reasoning and Problem-Solving 40.00 43.85
7) Social Cognition 42.33 49.86
8) Overall Cognitive Composite 32.9 40.16*
AUS/DUS
1) Overall Substance Use 2.53 1.95*
2) Alcohol 1.98 1.64*
3) Marijuana 1.76 1.39*
4) Tobacco 1.79 1.81
*p < 0.05 as compared to value for baseline assessment
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was no change in severity of negative symptoms from
baseline to 6-month assessment (t = −1.59; p = 0.13).
Social and educational/vocational functioning
Baseline and 6-month follow-up scores for the SFS sub-
scales are presented in Table 2. Overall, there was an
increase in total social functioning over the first 6
months of EPICENTER care (total SFS M = 108.08 vs.
118.92; t = 3.08; p = 0.02). With regard to SFS subscales,
the independence-competence subscale increased over
the first 6 months of EPICENTER care (t = 2.73; p = 0.03),
indicating that participants perceived themselves as more
competent in the independent completion of tasks of daily
living. There was no statistically significant change in any
other SFS subscale from baseline to 6-month assessment.
Participation in competitive employment/education in-
creased over the first 6 months of EPICENTER care.
More specifically, the percentage of participants engaged
in part-time or greater work/school increased from 38 %
at baseline to 49 % after 6 months of EPICENTER care
(t = 5.98; p < 0.01).
Cognitive functioning
Baseline and 6-month follow-up scores for the MCCB
are depicted in Table 2. There was a statistically signifi-
cant increase in the overall composite cognition score
for individuals participating in EPICENTER care (t =
3.14; p = 0.03). With regard to the individual MCCB
subscales, there were statistically significant improve-
ments in verbal learning (t = 2.54; p = 0.01) and process-
ing speed from baseline to 6-month assessment (t =
5.05; p < 0.01). There was also a trend suggesting pos-
sible improvements in visual learning from baseline to
6-month assessment (t = 2.03; p = 0.08). Of note, the
magnitude of these improvements exceed changes that
would be expected due to repeated administration of
the MCCB alone (i.e., practice effects [89]).
Substance use
Baseline and 6-month follow-up scores for the AUS/
DUS are presented in Table 2. Participants’ overall sub-
stance use declined from baseline to 6-month follow-up
(t = −5.55; p = 0.01). Among our sample, the three most
frequently used substances at baseline were alcohol
(63 %), tobacco (53 %), and marijuana (48 %). Although
participants’ use of alcohol (t = −2.34; p = 0.03) and
marijuana (t = −3.16; p < 0.01) both declined from base-
line to 6-month assessment, there was no change in par-
ticipants’ use of tobacco during the first 6 months of
EPICENTER care (t = 0.18; p = 0.86).
Service utilization and cost-effectiveness
Service utilization for EPICENTER participants is summa-
rized in Table 3. Individuals with first-episode psychosis
participated in an average of 14.94 EPICENTER-related
outpatient mental health visits during the first 6 months
of EPICENTER care. The number of episodes of in-
patient psychiatric hospitalization (t = −3.29; p < 0.01),
nights of inpatient hospitalization (t = −2.54; p = 0.01),
and contacts with the legal system (t = −2.11; p < 0.04)
were lower in the first 6 months of EPICENTER care as
compared to the 6 month period prior to the start of
EPICENTER care. Conversely, there was a near signifi-
cant increase in the number of non-EPICENTER out-
patient mental health visits during the first 6 months of
EPICENTER care (t = 2.18; p = 0.07). Although anti-
psychotic medication dose declined from the baseline to
6-month assessment, this change did not meet criteria for
statistical significance (t = −0.99; p = 0.34). Daily doses of
antipsychotic medication (chlorpromazine equivalents)
would be considered low (i.e., ≤400 mg) at baseline and
after 6 months of EPICENTER care [90].
Per person cost of services are presented in Fig. 2.
The cost of services received by individuals during the
6-month period prior to the start of EPICENTER care
(M = $43,456) was greater than the cost of services dur-
ing the first 6 months of EPICENTER care (M = $26,355;
t = −3.00; p < 0.01). Care elements contributing to this cost
savings included reductions in costs associated with
inpatient hospitalizations ($27,480 vs. $10,367; t = −3.24;
p < 0.01) and contact with the legal system ($8,604 vs.
$3,169; t = −2.10; p = 0.04). There was a near significant
increase in the costs associated with non-EPICENTER
outpatient mental health services during the first 6
months of EPICENTER care ($477 vs. $854; t = 2.16; p =
0.07). There was no change in costs associated with finan-
cial support provided by family members, cost of anti-
psychotic medications, or costs associated with being
unemployed and not in school.
The per person cost of providing EPICENTER care to
study participants was $6,136. Dividing the difference of
the total costs for the pre-EPICENTER and EPICENTER
treatment periods ($17,101) by this value reveals that for
every $1 spent on EPICENTER care, $2.79 dollars were
saved during the first 6 months of treatment.
Discussion
The results of the current report highlight the potential
clinical effectiveness of a multi-component psycho-
social intervention package for first-episode psychosis.
On average, individuals participating in EPICENTER
care showed improvements in symptomatology, social
functioning, educational/vocational functioning, cogni-
tive functioning, and substance use during the first 6
months of treatment. These improvements occurred
despite the fact that, on average, participants (i) were
already taking antipsychotic medication prior to study
enrollment and (ii) did not experience an increase in
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antipsychotic medication dose during the course of the
study. In total, these results add to the growing literature
with regard the potency of psychosocial interventions–
and multi-component psychosocial intervention pack-
ages–provided early in the course of a psychotic disorder
[45, 91, 92].
Yet, at the same time, care should be taken to avoid
overly-enthusiastic views of the clinical benefits of the
EPICENTER intervention package. Certain key out-
comes among our participants (i.e., tobacco use and
severity of negative symptoms) did not improve over the
first 6-months of EPICENTER care. Likewise, although
we found improvements in global measures of social and
cognitive functioning among individuals with first-episode
psychosis, analysis of the subcomponents of these global
measures suggests a more conservative interpretation. For
example, among the six subcomponents of social func-
tioning used to calculate an overall score for the Social
Functioning Scale, only one subscale increased signifi-
cantly over the first 6 months of EPICENTER care (i.e.,
independence-competence). Likewise, only two of seven
subcomponents used to calculate the overall cognitive
functioning score for the MATRICS Consensus Cognitive
Battery increased during the first 6 months of EPICEN-
TER care (i.e., verbal learning and processing speed).
Moreover, with the exception of the social cognition sub-
scale, performance on the remaining subscales remained
0.5–1.0 standard deviations below the norm for individ-
uals without psychotic disorders (i.e., T = 50) following 6
months of EPICENTER care. In total, these data highlight
the need for continued investigations of intervention strat-
egies with which to further improve clinical and functional
outcomes among individuals with first-episode psychosis.
With regard to service utilization and cost of care,
the data are more encouraging. More specifically, the
average cost of care during the first 6 months of EPI-
CENTER participation was lower than the average cost
during the 6 months prior to joining EPICENTER.
These savings occurred despite the additional costs as-
sociated with the receipt of EPICENTER care and were
driven primarily by reductions in the utilization of in-
patient psychiatric services and contacts with the legal
system. These savings are especially valuable given the
high cost of care of individuals with first-episode psych-
osis. More specifically, the per person 12-month cost of
care among our sample of individuals with first-episode
psychosis was $69,810—a cost value noticeably greater
than that reported in other cost of care studies that did
not limit their sample to individuals early in the course
of their psychotic illness [5, 93, 94].
Table 3 Service utilization during 6-month period prior to epicenter care versus during first 6 months of epicenter care
6-Month Period Prior to EPICENTER Care First 6 Months of EPICENTER Care
Outpatient Mental Health Visits (Non-EPICENTER) M = 14.59 M = 26.13
Outpatient Mental Health Visits (EPICENTER) N/A M = 14.94
Antipsychotic Medication (chlorpromazine equivalent) M = 331.74 mg M = 288.72 mg
Inpatient Hospitalization (Number of Episodes) M = 0.88 M = 0.33*
Inpatient Hospitalizations (Number of Days) M = 13.18 M = 4.80*
Contact with the Legal System (Number of Episodes) M = 2.00 M = 0.73*
*p < 0.05 as compared to value for 6 month period prior to EPICENTER care
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Despite the focus of the current investigation on psy-
chosocial treatments, it is important not to overlook the
importance of pharmacological interventions in the
treatment of first-episode psychosis. The clinical benefits
of such interventions are well documented in the psych-
osis literature [95]. As noted earlier, most participants
were already taking antipsychotic medication prior to
study enrollment, and the average per-participant dose
of antipsychotic medication did not decline over the
course of the study. Given the high rates of medication
discontinuation/non-compliance reported in naturalistic
studies of individuals with first-episode psychosis [96],
the relative stability of medication dose among EPICEN-
TER participants is particularly noteworthy and may
have contributed to the positive clinical and cost out-
comes among these individuals. Although not formally
assessed, it may be that an unintended benefit of partici-
pation in EPICENTER care is the facilitation of greater
medication adherence among study participants. This
hypothesis comports with previous evidence that indi-
viduals participating in certain evidence-based psycho-
social interventions for psychosis may display very high
levels of medication adherence (e.g., multifamily group psy-
choeducation [68]). Ultimately, future studies are needed
to more clearly unpack the association between participa-
tion in multi-component psychosocial treatment packages
and adherence to pharmacological interventions among
individuals with first-episode psychosis.
It is important to note that this study did suffer from a
number of limitations—most notably the lack of a study
design in which participants were randomly assigned to
EPICENTER care versus usual care for first-episode
psychosis in our community. With our current study de-
sign, it is impossible to rule out the possibility that the
improvement in clinical outcomes and cost of care for
individuals with first-episode psychosis may simply re-
flect the natural course of psychotic disorders and are
not a result of participation in EPICENTER care. It
seems unlikely, though, that this could completely ac-
count for our findings given the overwhelming evidence
that many of the outcomes investigated in this study (e.g.,
cognition, social functioning, and educational/vocational
functioning) typically worsen or remain stable over the
early natural course of psychotic disorders [97–100].
Conclusions
The results of our study suggest that multi-component
psychosocial interventions for first-episode psychosis
provided in the US mental health system may be both
clinically-beneficial and cost-effective. Although add-
itional research is needed, these findings provide pre-
liminary support for the growing delivery of specialized
multi-component interventions for first-episode psych-
osis within the United States.
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